International Headache Society. (2018). International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1-211.
[2]
Goadsby, P. J., & Sprenger, T. (2010). Current practice and future directions in the prevention and acute management of migraine. The Lancet Neurology, 9(3), 285-298.
[3]
Silberstein, S. D. (2015). Migraine pathophysiology and its clinical implications. Headache: The Journal of Head and Face Pain, 55(1), 1-12.
[4]
Dodick, D. W. (2018). A review of current treatments for migraine. JAMA, 319(18), 1864-1866.
[5]
Katsarava, Z., et al. (2012). Refractory chronic migraine: A consensus statement on classification and terminology. Cephalalgia, 32(12), 863-872.
[6]
Lipton, R. B., et al. (2019). Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 92(8), 355-362.
[7]
Aurora, S. K., et al. (2010). Botulinum neurotoxin for the treatment of migraine. Headache: The Journal of Head and Face Pain, 50(5), 839-843.
[8]
Diener, H. C., et al. (2019). CGRP monoclonal antibodies for migraine prevention. The New England Journal of Medicine, 381(12), 1170-1172.
[9]
Bigal, M. E., & Lipton, R. B. (2009). Concepts and mechanisms of migraine chronification. Headache: The Journal of Head and Face Pain, 49(1), 26-35.
[10]
Hadjikhani, N., et al. (2013). Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the National Academy of Sciences, 110(12), 4680-4685.